RB...LAJD's subs Diagnostech is now moving onto the shelves in S Africa w/their HIV test and they are waiting for a further app from S. Africa ref another product. But the most significant potential for Diagnostech right now is w/their TB test. It has certain characteristics that may give the product an edge over competing tests. My best guess is that the test is pending approval in several countries including the Asian continent...LAJD is OTC BB fully filing. Closed .13/.16 on 450,000 shares yest...wayyyyyyyy over avg vol. Do your own dd. 20m shares outstanding...from November '99 10q:
gpg
Diagnostic Products
La Jolla Diagnostics' subsidiary, DiagnosTech, Inc. is developing and marketing
clinical diagnostic products using immunologic and molecular biologic
technologies.
RAPID DIAGNOSTIC PRODUCTS
DiagnosTech has a line of products that now consists of nine self-contained,
rapid, point-of-care diagnostics test for:
Active M. tuberculosis (TB) disease
HIV I and II (AIDS) infection using serum/plasma
HIV I and II (AIDS) infection using whole blood
HIV I and II (AIDS) infection using saliva
H. pylori infection (the causative agent in over 90% of ulcers)
Hepatitis B (HBsAg)
Pregnancy
Trypanasoa cruzi infection (Chagas disease: a common parasitic infection)
Toxoplasma gondii infection (a common infection among AIDS patients)
The Company believes each of these diagnostic products to be uniquely
advantageous secondary to certain proprietary technology, know-how, and
formulations employed by the Company, and that the TB test in particular has no
equivalent in the marketplace. Each test requires only a very small sample of
the patient's blood, serum, urine, or saliva, as the case may be. Each test
gives an accurate result in 1 to 5 minutes. These tests can easily be
performed by any healthcare worker, semi-skilled technician, or by the patients
themselves. They are extremely rugged, require no refrigeration, and have a
shelf life of 12 to 18 months. No special equipment is required to perform any
test. Each test addresses a large and growing market both domestically and
internationally.
Each of the diagnostic tests manufactured and marketed represent state-of-the-
art technology in that they are rapid, accurate, easy-to-use, and inexpensive.
These characteristics make the products ideal for both the U.S. and overseas
markets. Changes in the economics of medicine increasingly favor products that
can be employed economically and effectively at the point-of-care. Outside of
the industrialized world, citizens of emerging economies seek access to
healthcare as a high priority. Tests that address significant medical needs,
are available at a modest price, and require no special instrumentation, are in
high demand.
DiagnosTech has begun to receive orders for its products, particularly the TB
and HIV Rapid Tests. |
